Prophase Labs (PRPH) Stock Price

Prophase Labs Price

NASDAQ·CLOSED
0.01
​
Market closed

Revenue at Prophase Labs has contracted by 11.3% per year over the past 19 years to 4.35 M USD. Earnings per share have grown at 53.1% per year over the last 9 years. For Prophase Labs, the net margin of -339.3% is down versus 7.9% a few years ago. At today's price the dividend yield works out to roughly 60,000.00%. The payout ratio is around 53% of earnings.

Prophase Labs stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Prophase Labs business model & stock analysis

ProPhase Labs, Inc. generates revenue through the sale of over-the-counter consumer healthcare products and dietary supplements. The company develops and markets TK Supplements, featuring LEGENDZ XL for male sexual enhancement, TRIPLE EDGE XL for daily energy and stamina, and SUPER PROSTAFLOW plus for prostate and urinary health. ORXx Complete, a dietary supplement, and ORXx cough/cold drops are also sold to national wholesalers, distributors, and retail chains including pharmacies and mass merchandise stores. The firm targets health-conscious consumers seeking natural solutions through its OTC drug and supplement lines. Its products are distributed via national wholesalers and retailers such as independent and chain drugstores, food stores, and mass merchandise outlets. ProPhase Labs focuses on direct sales to these established retail segments without third-party branding or partnerships. Revenue streams are derived from the consistent demand for male enhancement, energy, and health supplements within the OTC market. The company's product portfolio caters specifically to customers interested in natural health products, with no additional services or digital platforms beyond physical product sales.

Frequently asked questions about Prophase Labs

7 analysts currently rate the Prophase Labs stock: 6 recommend buying, 1 holding and 0 selling.

Converted at the current exchange rate, the Prophase Labs share trades at 0.01 EUR (0.01 USD).

The Prophase Labs share (PRPH) is listed on 1 stock exchanges, including: NASDAQ (PRPH).

The expected revenue of Prophase Labs is 41.69 M USD. This figure is based on current financial data and reflects the company's business performance.

The profit cannot currently be calculated for Prophase Labs.

The P/E ratio cannot be calculated for Prophase Labs at the moment.

The price-to-sales ratio (P/S) of Prophase Labs is currently 0.00. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Prophase Labs stock.

The Eulerpool Quality Score for Prophase Labs is 2/10.

The ISIN of Prophase Labs is US74345W2070. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Prophase Labs is A1CYM1. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Prophase Labs is PRPH. The ticker symbol is used to trade Prophase Labs shares on the stock exchange.

Fair ValueTerminal
0.01 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
90,520.83 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Jan 16, 1984
ISIN
US74345W2070
Cusip
74345W108
Sedol
2738332
Market capitalization
20,463.00 USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
—
P/S
P/Se
0.00
EV/EBIT
—
P/B Ratio
0.01
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-121.58 %
Last updated Nov 6, 2026, 3:43 AM